Pharsight

Drugs that contain Acalabrutinib Maleate

1. Calquence patents expiration

CALQUENCE's oppositions filed in EPO
CALQUENCE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7459554 ASTRAZENECA Imidazopyrazine tyrosine kinase inhibitors
Nov, 2026

(2 years from now)

US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(8 years from now)

US11059829 ASTRAZENECA Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate
Jul, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(8 years from now)

US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(8 years from now)

US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(10 years from now)

US11771696 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2022

NCE-1 date: 31 October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination wi...

Dosage: TABLET;ORAL

More Information on Dosage

CALQUENCE family patents

Family Patents